Fairmount Funds Management LLC bought CBIO
December 4, 2025 · Form 4 insider transaction
Fairmount Funds Management LLC bought 131,434 shares of Crescent Biopharma, Inc. at $13.41 per share, a transaction worth $1.76M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.; Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.